|
ZGNX's Revenue Growth by Quarter and Year
Zogenix Inc 's Revenue results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
ZGNX Revenue (in millions $) |
FY 2021 |
FY 2020 |
FY 2019 |
FY 2018 |
IV Quarter |
December |
26.61
|
2.86
|
3.01
|
2.13
|
III Quarter |
September |
22.61
|
1.03
|
4.05
|
1.03
|
II Quarter |
June |
18.79
|
1.09
|
3.16
|
0.83
|
I Quarter |
March |
13.68
|
-6.57
|
3.18
|
0.00
|
FY |
|
81.69
|
-1.59
|
13.40
|
3.99
|
ZGNX Revenue fourth quarter 2021 Y/Y Growth Comment |
Zogenix Inc reported Revenue surge of 830.31% year on year in the fourth quarter 2021, to $ 26.61 millions, this is lower than Zogenix Inc 's recent average Revenue surge of 5.585519069102E+15%.
Looking into fourth quarter 2021 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue growth. While Zogenix Inc ' s Revenue doubling of 830.31% ranks overall at the positon no. 91 in the fourth quarter 2021.
|
ZGNX Revenue ( Y/Y Growth %) |
2021
|
2020 |
2019 |
2018 |
IV Quarter |
December |
830.31 % |
-4.98 % |
41.31 % |
- |
III Quarter |
September |
2095.15 % |
-74.57 % |
293.2 % |
-85.55 % |
II Quarter |
June |
1623.85 % |
-65.51 % |
280.72 % |
-69.26 % |
I Quarter |
March |
- |
- |
- |
- |
FY |
|
- |
- |
235.84 % |
-80.84 % |
ZGNX Revenue (Quarter on Quarter Growth %) |
2021
|
2020 |
2019 |
2018 |
IV Quarter |
December |
17.68 % |
177.67 % |
-25.68 % |
106.8 % |
III Quarter |
September |
20.33 % |
-5.5 % |
28.16 % |
24.1 % |
II Quarter |
June |
37.35 % |
- |
-0.63 % |
- |
I Quarter |
March |
378.32 % |
- |
49.3 % |
- |
FY (Year on Year) |
|
- |
- |
235.84 % |
-80.84 % |
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
1.0E+17 % |
5.585519069102E+15 % |
-100 % |
|
|
(Dec 31 2017) |
|
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
1.0E+17 % |
5.585519069102E+15 % |
-100 % |
|
|
(Dec 31 2017) |
|
Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021 |
Zogenix Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
4.6893731119994E+16 % |
1.3792273858822E+15 % |
-100 % |
(Mar 31 2018) |
|
|
ZGNX's IV. Quarter Q/Q Revenue Comment |
Zogenix Inc achieved in the IV. Quarter 2021 below company average Revenue jump of 17.68% quarter on quarter, to $ 26.61 millions.
Within Major Pharmaceutical Preparations industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Zogenix Inc 's Revenue growth quarter on quarter, overall rank is 875. |
|
|
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
4.6893731119994E+16 % |
1.3792273858822E+15 % |
-100 % |
(Mar 31 2018) |
|
|
ZGNX's IV. Quarter Q/Q Revenue Comment |
Zogenix Inc achieved in the IV. Quarter 2021 below company average Revenue jump of 17.68% quarter on quarter, to $ 26.61 millions.
Within Major Pharmaceutical Preparations industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Zogenix Inc 's Revenue growth quarter on quarter, overall rank is 875. |
|
Zogenix Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending (Dec 31 2021) |
12 Months Ending (Sep 30 2021) |
12 Months Ending (Jun 30 2021) |
12 Months Ending (Mar 31 2021) |
12 Months Ending (Sep 30 2020) |
Cumulative Revenue 12 Months Ending |
$ 81.69 |
$ 57.94 |
$ 36.37 |
$ 18.66 |
$ -1.59 |
Y / Y Revenue Growth (TTM) |
- |
- |
2201.58 % |
411.62 % |
- |
Year on Year Revenue Growth Overall
Ranking |
# 109 |
# 0 |
# 25 |
# 30 |
# 161 |
Seqeuential Revenue Change (TTM) |
40.98 % |
59.34 % |
94.84 % |
- |
- |
Seq. Revenue Growth (TTM) Overall
Ranking |
# 391 |
# 52 |
# 33 |
# 67 |
# 0 |
Cumulative Revenue growth
Comment |
Zogenix Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 830.31% year on year, to $ 82 millions if the fiscal year would have ended in Dec 31 2021. Zogenix Inc 's trailing twelve months Revenue growth was higher than company's average 108.63% and higher than % growth in Sep 30 2021. But sequential increase was beneth at 40.98 % from $57.94 millions recorded in the period from Sep 30 2021 to Sep 30 2020. There is stagnation developing, more evident as we look at average Q/Q TTM historic rise what is better at108.63%. In the Dec 31 2021 period, Zogenix Inc had cumulative twelve months Revenue of $ 82 millions compare to of $ -2 millions a year ago. It is revival, but modest, reporting beneth average 40.98 % Revenue increase, from $57.94 millions from the twelve months ending in the quarter Sep 30 2021 Jacob Taylor said.
In the Healthcare sector 37 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 109. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 52 |
Sector |
# 109 |
S&P 500 |
# 391 |
|
Cumulative Revenue growth
Comment |
Zogenix Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 830.31% year on year, to $ 82 millions if the fiscal year would have ended in Dec 31 2021. Zogenix Inc 's trailing twelve months Revenue growth was higher than company's average 108.63% and higher than % growth in Sep 30 2021. But from the previous reporting period increase was slower at 40.98 % from $57.94 millions recorded in twelve months ending a quarter before Jacob Taylor went on. It appears to be slowdown happening, more noticeable observing the typical sequential historic advancement which is higher at 108.63% Jacob Taylor published. The momentum was much higher from the previous reporting period showed at 40.98 % jump from $57.94 millions in the period from Sep 30 2021 to Sep 30 2020. In the Dec 31 2021 period, Zogenix Inc had cumulative twelve months Revenue of $ 82 millions compare to of $ -2 millions a year ago. Singns of recovery, but very slow one, reporting beneth usual 40.98 % Revenue rise, from $57.94 millions from the twelve months ending in the quarter before Jacob Taylor mentioned.
In the Healthcare sector 37 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 109. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 52 |
Sector |
# 109 |
S&P 500 |
# 391 |
Companies with similar Revenue jump for the quarter ending Dec 31 2021 within Healthcare Sector | Y/Y Change % | Revenue for the quarter ending Dec 31 2021 | Kazia Therapeutics Limited | 1,426.13% | $ 1,426.131 millions | Inmune Bio Inc | 1,393.22% | $ 1,393.221 millions | Guardion Health Sciences Inc | 1,213.59% | $ 1,213.587 millions | Moderna Inc | 1,163.44% | $ 1,163.436 millions | Albireo Pharma inc | 1,097.39% | $ 1,097.386 millions | Option Care Health Inc | 1,023.60% | $ 1,023.599 millions | Genfit S a | 1,003.11% | $ 1,003.106 millions | Ethema Health Corporation | 967.17% | $ 967.166 millions | Dynavax Technologies Corporation | 897.80% | $ 897.801 millions | Inspiremd Inc | 789.87% | $ 789.873 millions | Prophase Labs Inc | 774.63% | $ 774.627 millions | Cytokinetics Incorporated | 727.13% | $ 727.135 millions | Theralink Technologies Inc | 706.69% | $ 706.691 millions | Beyondspring Inc | 650.56% | $ 650.556 millions | Meiragtx Holdings Plc | 504.51% | $ 504.513 millions | Guided Therapeutics Inc | 492.00% | $ 492.000 millions | Lftd Partners Inc | 482.17% | $ 482.175 millions | Cardiff Lexington Corporation | 465.13% | $ 465.127 millions | Lumos Pharma Inc | 450.00% | $ 450.000 millions | Baudax Bio Inc | 426.32% | $ 426.316 millions |
|